Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, Leyssen M. Szenborn L, et al. Among authors: leyssen m. Pediatr Infect Dis J. 2013 Jul;32(7):777-85. doi: 10.1097/INF.0b013e31828d6b20. Pediatr Infect Dis J. 2013. PMID: 23838777 Clinical Trial.
A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.
Thollot F, Scheifele D, Pankow-Culot H, Cheuvart B, Leyssen M, Ulianov L, Miller JM. Thollot F, et al. Among authors: leyssen m. Pediatr Infect Dis J. 2014 Dec;33(12):1246-54. doi: 10.1097/INF.0000000000000468. Pediatr Infect Dis J. 2014. PMID: 25037033 Clinical Trial.
Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
Khatami A, Snape MD, Ohene-Kena B, Young K, Oeser C, Michaelis LJ, Macleod E, Smee H, Van Der Meeren O, Leyssen M, Caubet M, Yu LM, Heath PT, Faust SN, Finn A, Pollard AJ. Khatami A, et al. Among authors: leyssen m. Pediatr Infect Dis J. 2013 Jun;32(6):675-81. doi: 10.1097/INF.0b013e31828672a7. Pediatr Infect Dis J. 2013. PMID: 23348809 Clinical Trial.
Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
Klein NP, Abu-Elyazeed R, Cornish M, Leonardi ML, Weiner LB, Silas PE, Grogg SE, Varman M, Frenck RW, Cheuvart B, Baine Y, Miller JM, Leyssen M, Mesaros N, Roy-Ghanta S. Klein NP, et al. Among authors: leyssen m. Vaccine. 2017 Jun 16;35(28):3564-3574. doi: 10.1016/j.vaccine.2017.05.018. Epub 2017 May 20. Vaccine. 2017. PMID: 28536030 Free article. Clinical Trial.
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Langley JM, Aggarwal N, Toma A, Halperin SA, McNeil SA, Fissette L, Dewé W, Leyssen M, Toussaint JF, Dieussaert I. Langley JM, et al. Among authors: leyssen m. J Infect Dis. 2017 Jan 1;215(1):24-33. doi: 10.1093/infdis/jiw453. Epub 2016 Sep 29. J Infect Dis. 2017. PMID: 27694633 Free PMC article. Clinical Trial.
48 results